Your browser doesn't support javascript.
loading
Reduced CC Chemokine Receptor 4 Expression in Tumor Cells after Lenalidomide Treatment for Adult T-Cell Leukemia/Lymphoma: A Case Report.
Shimizu, Masatomo; Yokote, Taiji; Hatooka, Jun; Kinoshita, Yuuki; Imagawa, Akihisa; Yasuda, Emi.
  • Shimizu M; Department of Internal Medicine, Osaka Medical and Pharmaceutical University, Takatsuki, Japan.
  • Yokote T; Department of Internal Medicine, Osaka Medical and Pharmaceutical University, Takatsuki, Japan.
  • Hatooka J; Department of Internal Medicine, Osaka Medical and Pharmaceutical University, Takatsuki, Japan.
  • Kinoshita Y; Department of Internal Medicine, Osaka Medical and Pharmaceutical University, Takatsuki, Japan.
  • Imagawa A; Department of Internal Medicine, Osaka Medical and Pharmaceutical University, Takatsuki, Japan.
  • Yasuda E; Department of Pathology, Osaka Medical and Pharmaceutical University, Takatsuki, Japan.
Case Rep Oncol ; 17(1): 602-607, 2024.
Article en En | MEDLINE | ID: mdl-39015631
ABSTRACT

Introduction:

CC chemokine receptor 4 (CCR4), which is involved in leukocyte migration, is expressed in most tumor cells in patients with adult T-cell leukemia/lymphoma (ATLL). Case Presentation Here we report the case of a 78-year-old man diagnosed with lymphoma-type ATLL expressing CCR4. The patient was administered two cycles of lenalidomide but died because of sepsis 5 months after the initial diagnosis. Autopsy revealed ATLL cells at several sites. Immunohistochemical analysis revealed that these ATLL cells had reduced CCR4 expression.

Conclusion:

The present case suggests that treatment should be carefully determined in ATLL with reference to a history of lenalidomide use and CCR4 expression.
Palabras clave